Señales en vivo de SRNE | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 may 2024 @ 15:46):

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases...

Stats
Volumen de hoy	116 904
Volumen promedio	283 571
Capitalización de mercado	11.03M
EPS	$-0.175 ( 2023-06-29 )
Próxima fecha de ganancias	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0200
ATR14	$0.00200 (10.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-17	Ji Henry	Buy	19 500	Common Stock
2023-03-17	Ji Henry	Sell	195	Put Option (obligation to buy)
2021-12-31	Janda Kim	Buy	0
2022-12-21	Ji Henry	Buy	300	Common Stock
2022-12-02	Ji Henry	Buy	200	Common Stock

INSIDER POWER
99.97
Last 96 transactions
Buy: 40 331 586 \| Sell: 980 682

Sorrento Therapeutics Inc Correlación

10 Correlaciones Más Positivas
EZGO	0.928
RMGC	0.928
AKTX	0.925
ADPT	0.925
ALLR	0.922
LULU	0.922
HUGE	0.921
BOXL	0.919
SLGG	0.919
CBLI	0.917

10 Correlaciones Más Negativas
CBAY	-0.967
IVCB	-0.952
TZPSU	-0.941
BCSA	-0.937
FUSN	-0.936
TZPS	-0.934
EBACU	-0.932
PFSW	-0.929
SWAV	-0.927
PAYS	-0.923

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sorrento Therapeutics Inc Finanzas

Annual	2022
Ingresos:	$62.84M
Beneficio Bruto:	$29.39M (46.77 %)
EPS:	$-1.330

FY	2022
Ingresos:	$62.84M
Beneficio Bruto:	$29.39M (46.77 %)
EPS:	$-1.330

FY	2021
Ingresos:	$52.90M
Beneficio Bruto:	$39.87M (75.37 %)
EPS:	$-1.450

FY	2020
Ingresos:	$39.99M
Beneficio Bruto:	$30.05M (75.14 %)
EPS:	$-1.300

Financial Reports:

No articles found.

Sorrento Therapeutics Inc

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.